脑啡肽酶抑制对心肌梗死后无症状左室收缩功能障碍患者左室重构的影响
本研究为前瞻性多中心随机双盲活性对照试验,比较沙库巴曲/缬沙坦与缬沙坦对心肌梗死后≥3个月、左室射血分数≤40%的无症状左室收缩功能障碍患者左室重构的影响。主要终点为52周左室收缩末期容积指数变化,结果两组无显著差异(调整组间差-1.9 mL/m2,95%CI -4.9至1.0,P=0.19)。
要点
- 沙库巴曲/缬沙坦未显著减少心肌梗死后无症状左室收缩功能障碍患者的左室收缩末期容积指数。
- NT-proBNP、hs-cTnI、左室舒张末期容积指数等次要终点亦无显著组间差异。
- 该人群使用沙库巴曲/缬沙坦未见显著逆转重构效应。
核心结论
- 在心肌梗死后晚期无症状左室收缩功能障碍患者中,与缬沙坦相比,沙库巴曲/缬沙坦未表现出显著的逆转重构效应。
研究设计与样本
- 前瞻性、多中心、随机、双盲、活性对照试验,纳入心肌梗死后≥3个月、左室射血分数≤40%、正在使用肾素-血管紧张素系统抑制剂(雷米普利等效剂量≥2.5 mg每日两次)及β受体阻滞剂(除非禁忌或不耐受)的患者,排除NYHA≥II级或有心衰症状体征者。
- 2018年7月至2019年6月随机93例患者,比较沙库巴曲/缬沙坦97/103 mg每日两次与缬沙坦160 mg每日两次。
主要发现
- 主要终点52周左室收缩末期容积指数变化:沙库巴曲/缬沙坦组与缬沙坦组调整组间差-1.9 mL/m2(95%CI -4.9至1.0),P=0.19。
- NT-proBNP、高敏心肌肌钙蛋白I、左室舒张末期容积指数、左房容积指数、左室射血分数、左室质量指数及患者整体变化评估均无显著组间差异。
关键数值与推荐
- 患者平均年龄60.7±10.4岁,心肌梗死中位时间3.6年(IQR 1.2-7.2),平均左室射血分数36.8%±7.1%,NT-proBNP中位数230 pg/mL(IQR 124-404)。
临床怎么用
- 对于心肌梗死后晚期无症状左室收缩功能障碍患者,沙库巴曲/缬沙坦在逆转左室重构方面未显示优于缬沙坦,临床决策需结合个体情况。
局限性
- 样本量较小(93例),可能不足以检测出小幅重构差异。
- 研究人群为无症状且心肌梗死后较晚期(中位3.6年),结果不能外推至急性期或有症状心衰患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with left ventricular (LV) systolic dysfunction after myocardial infarction are at a high risk of developing heart failure. The addition of neprilysin inhibition to renin angiotensin system inhibition may result in greater attenuation of adverse LV remodeling as a result of increased levels of substrates for neprilysin with vasodilatory, antihypertrophic, antifibrotic, and sympatholytic effects. METHODS: We performed a prospective, multicenter, randomized, double-blind, active-comparator trial comparing sacubitril/valsartan 97/103 mg twice daily with valsartan 160 mg twice daily in patients ≥3 months after myocardial infarction with a LV ejection fraction ≤40% who were taking a renin angiotensin system inhibitor (equivalent dose of ramipril ≥2.5 mg twice daily) and a β-blocker unless contraindicated or intolerant. Patients in New York Heart Association class ≥II or with signs and symptoms of heart failure were excluded. The primary outcome was change from baseline to 52 weeks in LV end-systolic volume index measured using cardiac magnetic resonance imaging. Secondary outcomes included other magnetic resonance imaging measurements of LV remodeling, change in NT-proBNP (N-terminal pro-B-type natriuretic peptide) and high-sensitivity cardiac troponin I, and a patient global assessment of change questionnaire. RESULTS: From July 2018 to June 2019, we randomized 93 patients with the following characteristics: mean age, 60.7±10.4 years; median time from myocardial infarction, 3.6 years (interquartile range, 1.2-7.2); mean LV ejection fraction, 36.8%±7.1%; and median NT-proBNP, 230 pg/mL (interquartile range, 124-404). Sacubitril/valsartan, compared with valsartan, did not significantly reduce LV end-systolic volume index; adjusted between-group difference, -1.9 mL/m2 (95% CI, -4.9 to 1.0); P=0.19. There were no significant between-group differences in NT-proBNP, high-sensitivity cardiac troponin I, LV end-diastolic volume index, left atrial volume index, LV ejection fraction, LV mass index, or patient global assessment of change. CONCLUSIONS: In patients with asymptomatic LV systolic dysfunction late after myocardial infarction, treatment with sacubitril/valsartan did not have a significant reverse remodeling effect compared with valsartan. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03552575.
引用
- Docherty KF, Campbell RT, Brooksbank KJM, et al. Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction. Circulation. 2021. PMID: 33983794. doi:10.1161/CIRCULATIONAHA.121.054892
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。